title: Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience.
abstract: Non-small cell lung cancer (NSCLC) is usually at advanced stage when it is diagnosed. There is no consensus about the standard treatment in elderly patients with advanced NSCLC. Generally, data regarding elderly patients with NSCLC are withdrawn from general NSCLC studies based on subgroup analyses and suggestions. We evaluated prognostic factors in elderly patients with advanced NSCLC. We reviewed retrospectively 338 patients from August 2005 to July 2009 in two centers in Turkey. Medical records of the patients≥65 years with advanced NSCLC were collected. Collected data included demographic informations, clinical assessments and information on treatment, toxicities and outcomes. Survival was estimated by using Kaplan-Meier method and prognostic factors were evaluated with log-rank and Cox regression tests. The median overall survival (OS) for the entire group was 15.4 months (95% CI: 12.7-18.0). In univariate analysis, weight loss, stage, combination therapy, second-line chemotherapy and tumor response (P<0.01) and performance status significantly affected OS (P<0.05). The median progression-free survival (PFS) was 10 months (95% CI: 8.4-11.6). In univariate analysis, there was only a significant association between tumor response and PFS (14.6 vs. 8.5 months; P<0.001). Multivariate analysis showed that only response to therapy was an important prognostic factor for OS (P<0.001). Survival of elderly patients with advanced NSCLC is significantly influenced by performance status, weight loss, stage, combination therapy, second-line chemotherapy and response to therapy. Not only age but also these factors may be kept in mind in the treatment planning of the elderly patients with NSCLC. These results may be of benefit in changing clinical practice in elderly patients with NSCLC who are often undertreated.
authors.affiliation: Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, and Department of Radiation Oncology, Marmara University School of Medicine, Istanbul, Turkey. ukefeli@yahoo.com
authors.forename: U
authors.initials: U
authors.lastname: Kefeli
authors.forename: S
authors.initials: S
authors.lastname: Kaya
authors.forename: B O
authors.initials: BO
authors.lastname: Ustaalioglu
authors.forename: A
authors.initials: A
authors.lastname: Bilici
authors.forename: A U
authors.initials: AU
authors.lastname: Kefeli
authors.forename: M E
authors.initials: ME
authors.lastname: Yildirim
authors.forename: M
authors.initials: M
authors.lastname: Seker
authors.forename: B
authors.initials: B
authors.lastname: Yilmaz
authors.forename: T
authors.initials: T
authors.lastname: Salepci
authors.forename: K
authors.initials: K
authors.lastname: Uygun
authors.forename: M
authors.initials: M
authors.lastname: Gumus
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D014421:Turkey